• Publications
  • Influence
Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients
We compared the efficacy and safety of valganciclovir with those of oral ganciclovir in preventing cytomegalovirus (CMV) disease in high‐risk seronegative solid organ transplant (SOT) recipients ofExpand
  • 712
  • 39
Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus
DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C2 Monitoring Versus Tacrolimus) was a 6‐month, open‐label, randomized, multicenter study which used American Diabetes Association/WorldExpand
  • 499
  • 25
Preparation and characterization of monoclonal antibodies reactive with porcine PBL.
Partially inbred miniature swine have been developed in this laboratory as a large animal model for immunologic studies. For many of these studies, a source of large quantities of well standardizedExpand
  • 274
  • 22
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action
  • M. Pescovitz
  • Medicine
  • American journal of transplantation : official…
  • 1 May 2006
Rituximab, chimeric anti‐human CD20, is approved for treatment of B‐cell lymphoma in adults. It is being used experimentally in other various immune‐related diseases such as immune thrombocytopenicExpand
  • 458
  • 20
Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients
ABSTRACT The pharmacokinetics of an orally administered valine ester of ganciclovir (GCV), valganciclovir (VGC), were studied. These were compared to the pharmacokinetics of oral and intravenous GCV.Expand
  • 309
  • 18
Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients
Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ transplant recipients. Oral valganciclovir is a more convenient alternative. In a randomized,Expand
  • 321
  • 16
Ganciclovir and Acyclovir Reduce the Risk of Post‐Transplant Lymphoproliferative Disorder in Renal Transplant Recipients
Given its association with Epstein‐Barr virus (EBV), there is considerable interest in assessing the impact of prophylactic anti‐viral therapy on post‐transplant lymphoproliferative disorder (PTLD).Expand
  • 228
  • 13
INTERLEUKIN-2-RECEPTOR BLOCKADE WITH DACLIZUMAB TO PREVENT ACUTE REJECTION IN RENAL TRANSPLANTATION
Background Monoclonal antibodies that block the high-affinity interleukin-2 receptor expressed on alloantigen-reactive T lymphocytes may cause selective immunosuppression. Daclizumab is a geneticallyExpand
  • 701
  • 9
Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.
Large between- and within-patient variability has been observed in the pharmacokinetics of mycophenolic acid (MPA). However, conflicting results exist about the influence of patient characteristicsExpand
  • 178
  • 9
Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients
Background. A randomized, double-blind study was conducted to evaluate the pharmacokinetics of ganciclovir following oral administration of ganciclovir or valganciclovir for prophylaxis ofExpand
  • 115
  • 8